Docetaxel (Docetaxel) Patent Expiration, LOE Window & CMS Spending
Docetaxel (Docetaxel) by Pfizer: FDA Orange Book LOE 2036-03-14, 22 AB generics, $7.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N022234 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-03-14 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 22 |
| 2024 CMS Total Public Spend | $7.8M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $6.6M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.